Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ventyx Biosciences, Inc. Director's Dealing 2021

Oct 21, 2021

33798_dirs_2021-10-20_2cb148cd-bf64-4f02-8b47-cc554750e138.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Ventyx Biosciences, Inc. (VTYX)
CIK: 0001851194
Period of Report: 2021-10-20

Reporting Person: Royston Aaron (Director, 10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1014267 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Stock $ Common Stock (3289742) Indirect
Series B Preferred Stock $ Common Stock (395027) Indirect

Footnotes

F1: Shares held by venBio SPV III, LLC ("venBio SPV"). venBio SPV is wholly owned and managed by venBio Global Strategic Fund III, L.P. ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. The Reporting Person, Robert Adelman and Corey Goodman are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio SPV. The Reporting Person disclaims beneficial ownership over the shares held by venBio SPV except to the extent of his pecuniary interest therein.

F2: All shares of the preferred stock, par value $0.0001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. The preferred stock has no expiration date.

F3: Shares held by venBio III. venBio GP is the sole general partner of venBio III. venBio Ltd is the sole general partner of venBio GP. The Reporting Person, Robert Adelman and Corey Goodman are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. The Reporting Person disclaims beneficial ownership over the shares held by venBio III except to the extent of his pecuniary interest therein.